Navigation Links
Cell-Wall Carbohydrate in Anthrax Bacterium Holds Promise for New Vaccines

Athens: It was just weeks following the 9/11 attacks in 2001, when the deadly letters made its way into several offices of the news media and two US senators//. The letters contained a virulent strain of anthrax bacteria, which killed five people and infected 17 others.

In a bid to ensuring the safety of citizens, researchers at the University of Georgia, teaming up with scientists at the federal Centers for Disease Control and Prevention (CDC) in Atlanta, have identified the structure of a unique cell-wall carbohydrate in B. anthracis.

The unique nature of the carbohydrate makes the molecule an important target for evaluating its role in virulence and survival of the anthrax bacterium, the development of new diagnostic tests and perhaps even as a new vaccine additive.

Russell Carlson of the department of biochemistry and molecular biology at the University of Georgia and faculty member at UGA’s Complex Carbohydrate Research Center (CCRC), was corresponding author on a paper reporting the research, which was just published in the online version of the Journal of Biological Chemistry. Other authors from the CCRC include Biswa Choudhury, Christine Leoff, Elke Saile and Elmar Kannenberg. Collaborators at CDC were Patricia Wilkins and Conrad P. Quinn.

Anthrax is a naturally occurring animal disease. This year alone there have been several large outbreaks in animals in the U.S. and Canada, so understanding the structure of important parts of B. anthracis has a wide variety of potential applications. The new UGA research is not directly about vaccine development, and much more research needs to be done before the full potential of this unique anthrax molecule is understood.

The problems facing researchers as they unravel all the molecular riddles of anthrax are enormous. There are more than 100 known strains of B. anthracis, and one of the most virulent is called the Ames Strain. It is this strain that was mail ed to victims in the fall of 2001.

Effective vaccines and antibiotics against anthrax do exist. Indeed, the federal government began Project BioShield, a $5.6 billion initiative, even before the last anthrax letter was delivered in 2001. Still, a New York Times story on September 18 reported that despite a $900 million “push to add a new anthrax vaccine to the stockpile,” there have been setbacks. The Times reported that “only a small fraction of the anticipated remedies are available.”

As a first step in understanding the structure and function of cell wall carbohydrates, the research team examined four Bacillus anthracis strains – Ames, Pasteur, Sterne and UT60 – and compared them to two related strains of Bacillus cereus, a soil-dwelling bacterium that causes food-borne illnesses. Cultures of these strains and the initial cell wall preparations were prepared by CDC researchers in their biosafety labs.

One important discovery in the just-reported research is that the newly discovered carbohydrate in the cell wall of B. anthracis is “species specific”; that is, of the strains tested, it was only found in the anthrax bacterium. This is one of several necessary conditions for a molecule that may be used to prepare rapid diagnostic tests for anthrax.

The research was supported by grants from the National Institutes of Health (to Carlson) and the U.S. Department of Energy (to the CCRC).


Related medicine news :

1. High-Carbohydrate diet plus exercise !
2. Carbohydrate-rich Diet In Diabetes Raises Blood Pressure
3. Low Carbohydrate Diet Packs No Bone Loss
4. Quality Of Dietary Carbohydrates May Determine Quality Of Eye Sight
5. Restriction of Carbohydrates to Prevent Alzheimers Disease
6. Low Carbohydrate Diet Still the First Choice for Diabetics
7. Food Rich in High Carbohydrate, Effective in Maintaining the Weight Loss
8. Role of Carbohydrate trigger in Obesity and Diabetes
9. Virus Can Mutate lethally With Help Of Carbohydrates
10. High Carbohydrate Food Brings on Sleep Faster
11. Anthrax drug doxycycline could stunt fetal growth
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: